Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: EN Paris
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

COX:FP

1.9890 EUR 0.1550 7.23%

As of 11:35:00 ET on 03/06/2015.

Company Profile for NicOx SA (COX)

NicOx develops pharmaceuticals using recently discovered properties of nitric oxide. The Company develops drugs-candidates for the potential treatment of inflammatory, cardiometabolic and ophthalmological diseases. NicOx's lead compound naproxcinod is developed for the relief of the signs and symptoms of osteoarthritis.

Contact Information

NicOx SA

1681 Route Des Dolines
Taissounieres HB4 BP 313
Valbonne, 06560
France
Phone: 33-4-97-24-53-00
Fax: 33-4-97-24-53-99

Key Executives for NicOx SA (COX)

Michele GarufiChairman/CEO/Co-FounderEvelyne NguyenChief Financial Officer
Michael BergaminiExec VP/Chief Scientific OfcrPhilippe MasquidaExec VP/Mng Dir:European & Intl Ops
Gavin SpencerExec VP:Corporate DevelopmentDavide BuffoniManaging Director:Spain
Benito GuerraManaging Director:ItalyTorsten CorneliusManaging Director:Germany
Jean-Francois MazelierManaging Director:France

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil